A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants With Chronic Obstructive Pulmonary Disease (ZION)
Latest Information Update: 12 May 2025
At a glance
- Drugs Solrikitug (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
Most Recent Events
- 04 May 2025 Planned End Date changed from 31 Aug 2025 to 31 Oct 2026.
- 04 May 2025 Planned primary completion date changed from 30 Apr 2025 to 30 Jun 2026.
- 24 Feb 2025 Planned number of patients changed from 135 to 171.